Pfizer India - Public Comps and Valuation Multiples

Pfizer India Overview

About Pfizer India

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company has only one segment which is Pharmaceuticals and it operates in domestic market.

Founded

1950

HQ

Employees

1.6K+

Website

pfizerltd.co.in

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $267M

LTM EBITDA $88.9M

EV

$2.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Pfizer India Financials

As of September 2025, Pfizer India reported last 12-month revenue of $267M and EBITDA of $88.9M.

In the same period, Pfizer India generated $172M in LTM gross profit and $77.3M in net income.

See Pfizer India valuation multiples based on analyst estimates

Pfizer India P&L

In the most recent fiscal year, Pfizer India reported revenue of $257M and EBITDA of $122M.

Pfizer India expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Pfizer India valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$267M	XXX	$257M	XXX	XXX	XXX
Gross Profit	$172M	XXX	$166M	XXX	XXX	XXX
Gross Margin	64%	XXX	64%	XXX	XXX	XXX
EBITDA	$88.9M	XXX	$122M	XXX	XXX	XXX
EBITDA Margin	33%	XXX	48%	XXX	XXX	XXX
EBIT	$92.9M	XXX	$76.8M	XXX	XXX	XXX
EBIT Margin	35%	XXX	30%	XXX	XXX	XXX
Net Profit	$77.3M	XXX	$86.6M	XXX	XXX	XXX
Net Margin	29%	XXX	34%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Pfizer India including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $267M. EBITDA for the last twelve months was $88.9M. In the most recent fiscal year, Pfizer India achieved $257M in revenue and $122M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$267M	Analyst estimates available to subscribers	$257M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$172M	Analyst estimates available to subscribers	$166M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	64.5% gross margin	Analyst estimates available to subscribers	64.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$88.9M	Analyst estimates available to subscribers	$122M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	33.3% EBITDA margin	Analyst estimates available to subscribers	47.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$92.9M	Analyst estimates available to subscribers	$76.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	34.8% EBIT margin	Analyst estimates available to subscribers	29.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$77.3M	Analyst estimates available to subscribers	$86.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	28.9% net profit margin	Analyst estimates available to subscribers	33.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Pfizer India

This financial data table provides comprehensive performance metrics for Pfizer India, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Pfizer India generated $267M in revenue over the last twelve months.
The company achieved $88.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $172M.
Net income over the last twelve months reached $77.3M.

Fiscal Year Performance

In the most recent fiscal year, Pfizer India reported $257M in total revenue.
Fiscal year EBITDA was $122M.
The company maintained a gross profit margin of 64.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 47.6%.
Net profit margin reached 33.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Pfizer India. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Pfizer India Stock Performance

Pfizer India has current market cap of INR 245B (or $2.8B), and EV of INR 218B (or $2.5B).

Market Cap Evolution

Pfizer India Stock Data

As of October 17, 2025, Pfizer India's stock price is INR 5354 (or $60).

See Pfizer India trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.5B	$2.8B	XXX	XXX	XXX	XXX	$1.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Pfizer India Valuation Multiples

Pfizer India's trades at 9.7x EV/Revenue multiple, and 21.4x EV/EBITDA.

See valuation multiples for Pfizer India and 15K+ public comps

Pfizer India Financial Valuation Multiples

As of October 17, 2025, Pfizer India has market cap of $2.8B and EV of $2.5B.

Equity research analysts estimate Pfizer India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pfizer India has a P/E ratio of 35.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV/Revenue	9.2x	XXX	9.7x	XXX	XXX	XXX
EV/EBITDA	27.7x	XXX	21.4x	XXX	XXX	XXX
EV/EBIT	26.5x	XXX	33.3x	XXX	XXX	XXX
EV/Gross Profit	14.3x	XXX	n/a	XXX	XXX	XXX
P/E	35.7x	XXX	34.3x	XXX	XXX	XXX
EV/FCF	29.8x	XXX	40.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pfizer India Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Pfizer India Margins & Growth Rates

Pfizer India's last 12 month revenue growth is 7%

Pfizer India's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Pfizer India's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pfizer India's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Pfizer India and other 15K+ public comps

Pfizer India Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	7%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	33%	XXX	45%	XXX	XXX	XXX
EBITDA Growth	11%	XXX	-7%	XXX	XXX	XXX
Rule of 40	52%	XXX	52%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	51%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial